These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 28530150)

  • 1. The roles of bile acids and applications of microencapsulation technology in treating Type 1 diabetes mellitus.
    Woodhams L; Al-Salami H
    Ther Deliv; 2017 Jun; 8(6):401-409. PubMed ID: 28530150
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-Loading Dose of Microencapsulated Gliclazide Formulation Exerted a Hypoglycaemic Effect on Type 1 Diabetic Rats and Incorporation of a Primary Deconjugated Bile Acid, Diminished the Hypoglycaemic Antidiabetic Effect.
    Golocorbin-Kon S; Calasan J; Milijasevic B; Vukmirovic S; Lalic-Popovic M; Mikov M; Al-Salami H
    Eur J Drug Metab Pharmacokinet; 2017 Dec; 42(6):1005-1011. PubMed ID: 28547295
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Morphological, Stability, and Hypoglycemic Effects of New Gliclazide-Bile Acid Microcapsules for Type 1 Diabetes Treatment: the Microencapsulation of Anti-diabetics Using a Microcapsule-Stabilizing Bile Acid.
    Mathavan S; Chen-Tan N; Arfuso F; Al-Salami H
    AAPS PharmSciTech; 2018 Oct; 19(7):3009-3018. PubMed ID: 30062539
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potential Applications of Gliclazide in Treating Type 1 Diabetes Mellitus: Formulation with Bile Acids and Probiotics.
    Mikov M; Đanić M; Pavlović N; Stanimirov B; Goločorbin-Kon S; Stankov K; Al-Salami H
    Eur J Drug Metab Pharmacokinet; 2018 Jun; 43(3):269-280. PubMed ID: 29039071
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comprehensive study of novel microcapsules incorporating gliclazide and a permeation enhancing bile acid: hypoglycemic effect in an animal model of Type-1 diabetes.
    Mathavan S; Chen-Tan N; Arfuso F; Al-Salami H
    Drug Deliv; 2016 Oct; 23(8):2869-2880. PubMed ID: 26610261
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Islet Microencapsulation: Strategies and Clinical Status in Diabetes.
    Omami M; McGarrigle JJ; Reedy M; Isa D; Ghani S; Marchese E; Bochenek MA; Longi M; Xing Y; Joshi I; Wang Y; Oberholzer J
    Curr Diab Rep; 2017 Jul; 17(7):47. PubMed ID: 28523592
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Release and swelling studies of an innovative antidiabetic-bile acid microencapsulated formulation, as a novel targeted therapy for diabetes treatment.
    Mooranian A; Negrulj R; Al-Sallami HS; Fang Z; Mikov M; Golocorbin-Kon S; Fakhoury M; Arfuso F; Al-Salami H
    J Microencapsul; 2015; 32(2):151-6. PubMed ID: 25265061
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel chenodeoxycholic acid-sodium alginate matrix in the microencapsulation of the potential antidiabetic drug, probucol. An in vitro study.
    Mooranian A; Negrulj R; Mikov M; Golocorbin-Kon S; Arfuso F; Al-Salami H
    J Microencapsul; 2015; 32(6):589-97. PubMed ID: 26190214
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bile acid bio-nanoencapsulation improved drug targeted-delivery and pharmacological effects via cellular flux: 6-months diabetes preclinical study.
    Mooranian A; Raj Wagle S; Kovacevic B; Takechi R; Mamo J; Lam V; Watts GF; Mikov M; Golocorbin-Kon S; Stojanovic G; Al-Sallami H; Al-Salami H
    Sci Rep; 2020 Jan; 10(1):106. PubMed ID: 31919411
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An advanced microencapsulated system: a platform for optimized oral delivery of antidiabetic drug-bile acid formulations.
    Mooranian A; Negrulj R; Mathavan S; Martinez J; Sciarretta J; Chen-Tan N; Mukkur TK; Mikov M; Lalic-Popovic M; Stojancevic M; Golocorbin-Kon S; Al-Salami H
    Pharm Dev Technol; 2015; 20(6):702-9. PubMed ID: 24798888
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of the bile acid chenodeoxycholic acid in the targeted oral delivery of the anti-diabetic drug gliclazide, and its applications in type 1 diabetes.
    Mathavan S; Chen-Tan N; Arfuso F; Al-Salami H
    Artif Cells Nanomed Biotechnol; 2016 Sep; 44(6):1508-19. PubMed ID: 26212118
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biguanide Pharmaceutical Formulations and the Applications of Bile Acid-Based Nano Delivery in Chronic Medical Conditions.
    Jones M; Ionescu CM; Walker D; Wagle SR; Kovacevic B; Chester J; Foster T; Johnston E; Kuthubutheen J; Brown D; Atlas MD; Mikov M; Mooranian A; Al-Salami H
    Int J Mol Sci; 2022 Jan; 23(2):. PubMed ID: 35055022
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Liver-targeted delivery of insulin-loaded nanoparticles via enterohepatic circulation of bile acids.
    Zhang Z; Li H; Xu G; Yao P
    Drug Deliv; 2018 Nov; 25(1):1224-1233. PubMed ID: 29791242
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bile acids and bile acid derivatives: use in drug delivery systems and as therapeutic agents.
    Faustino C; Serafim C; Rijo P; Reis CP
    Expert Opin Drug Deliv; 2016 Aug; 13(8):1133-48. PubMed ID: 27102882
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of allylamine-bile acid combinations on cell delivery microcapsules in diabetes.
    Mooranian A; Negrulj R; Al-Salami H
    J Microencapsul; 2016 Sep; 33(6):569-574. PubMed ID: 27574968
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Designing anti-diabetic β-cells microcapsules using polystyrenic sulfonate, polyallylamine, and a tertiary bile acid: Morphology, bioenergetics, and cytokine analysis.
    Mooranian A; Negrulj R; Al-Salami H; Morahan G; Jamieson E
    Biotechnol Prog; 2016 Mar; 32(2):501-9. PubMed ID: 26748789
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bile Acid Control of Metabolism and Inflammation in Obesity, Type 2 Diabetes, Dyslipidemia, and Nonalcoholic Fatty Liver Disease.
    Chávez-Talavera O; Tailleux A; Lefebvre P; Staels B
    Gastroenterology; 2017 May; 152(7):1679-1694.e3. PubMed ID: 28214524
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Microencapsulation of Coenzyme Q10 and bile acids using ionic gelation vibrational jet flow technology for oral delivery.
    Jones M; Walker D; Ionescu CM; Kovacevic B; Wagle SR; Mooranian A; Brown D; Al-Salami H
    Ther Deliv; 2020 Dec; 11(12):791-805. PubMed ID: 33225829
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bile acids as metabolic regulators.
    Li T; Chiang JY
    Curr Opin Gastroenterol; 2015 Mar; 31(2):159-65. PubMed ID: 25584736
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis of a novel polymer bile salts-(polyethylene glycol)2000-bile salts and its application to the liver-selective targeting of liposomal DDB.
    Chen ZP; Zhu JB; Chen HX; Xiao YY; Feng MS; Cai H; Chen J; Cai BC
    Drug Dev Ind Pharm; 2010 Jun; 36(6):657-65. PubMed ID: 20136497
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.